Table 3.

Overall and subgroup analyses for frail community-dwelling older patients with coronary artery disease (CAD) statin users vs non-users: multivariate and propensity score (PS) quintiles adjusted models

	Deaths	Patients	Person- years	Three-year mortality rate (n° events per 100 person-years)				Multivariable models*			PS quintiles adjusted models
				All	Statin use		Change†	HR	95% CI	p-value	HR	95% CI	p-value
					No	Yes
MPI-SVaMA risk group
MPI-SVaMA-1 mild risk	338	785	1442	23.4	33.1	15.7	−17.4	0.36	0.29-0.43	<0.001	0.45	0.37-0.55	<0.001
MPI-SVaMA-2 moderate risk	641	1096	1638	39.1	53.8	24.6	−29.2	0.39	0.32-0.47	<0.001	0.44	0.36-0.53	<0.001
MPI-SVaMA-3 severe risk	540	716	709	76.2	129.3	38.1	−91.2	0.19	0.14-0.28	<0.001	0.28	0.21-0.39	<0.001
Age
65-74.9 years	182	326	534	34.1	64.5	24.1	−40.4	0.24	0.16-0.34	<0.001	0.38	0.27-0.53	<0.001
75-84.9 years	574	1051	1637	35.1	53.3	23.4	−29.9	0.34	0.28-0.41	<0.001	0.45	0.38-0.54	<0.001
85 years	763	1220	1618	47.2	62.0	24.4	−37.6	0.37	0.30-0.45	<0.001	0.44	0.37-0.54	<0.001
All	1519	2597	3789	40.1	59.0	23.8	−35.2	0.35	0.30-0.39	<0.001	0.44	0.39-0.49	<0.001

MPI-SVaMA = Multidimensional Prognostic Index-Standardized Multidimensional Assessment Schedule for Adults and Aged Persons.

^*Models were adjusted for: age at SVaMA evaluation, sex, nursing care needs (VIP), cognitive status (VCOG), pressure sores risk (VPIA), activities of daily living (VADL), mobility (VMOB), social support (VSOC) (all MPI-SVaMA domains), the needing of care assistants, the main diagnoses of fractures, cancer, dementia, stroke, hypokinetic syndrome and cardiovascular, respiratory neurological or other diseases and number of all medications prescribed within one year before patient’s enrollment (tertiles).

^†Difference of mortality rates between statins users versus non-user.